Glycaemic remission in type 2 diabetes and subsequent microvascular and macrovascular outcomes: a systematic review and meta-analysis
In brief
Diabetes remission links to 32% fewer microvascular and 27% fewer cardiovascular events
Across five cohorts, people with type 2 diabetes remission had 32% lower microvascular risk and 27% lower cardiovascular risk than those without remission. These observational findings do not prove remission caused the reduction, since better health or risk-factor changes may help explain the association; remission should not replace ongoing complication checks and risk management.
- Journal
- Diabetes research and clinical practice (Q1)
- Published
- 7 October 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Chenglu Ruan, Xiang Zheng, Lin Wang
- PMID
- 42843768
- DOI
- 10.1016/j.diabres.2026.113600
Why clinicians should know about it
- Picked for Epidemiology (top studies of the week, 11 October 2026): Systematic review/meta-analysis of diabetes remission and vascular outcomes
Abstract
Type 2 diabetes remission may reduce the long-term burden of vascular complications, but the magnitude and consistency of this association remain uncertain. We systematically evaluated whether remission was associated with lower subsequent microvascular and macrovascular or cardiovascular risk compared with non-remission. PubMed/MEDLINE and Europe PMC were searched through 31 August 2026 for longitudinal cohorts comparing adults with and without biochemical remission. Eight reports from seven independent cohorts were included, with five cohorts contributing to quantitative vascular synthesis. Remission was associated with lower microvascular risk (pooled HR 0.68, 95% CI 0.59-0.77; I2 = 4.1%) and lower macrovascular or cardiovascular risk (pooled HR 0.73, 95% CI 0.61-0.87; I2 = 8.7%). Findings were consistent across lifestyle, routine-care, and metabolic-surgery settings. Additional cohorts associated remission with lower all-cause and cardiovascular mortality. However, risk of bias was moderate or serious because remission was not randomized and may reflect favorable post-baseline risk-factor changes. Type 2 diabetes remission is associated with substantially fewer subsequent vascular events, but causal attribution remains uncertain. Remission should complement, rather than replace, continued complication surveillance and multifactorial risk management.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.